← Back to patent-cliff list
倍他米松
Tier C — Watch / tradeBetamethasone
默沙东
Originator
1961
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：GR
Brand：Rinderon、Celestone
Indications (approved)：溃疡性直肠炎、超敏反应、类风湿关节炎、皮肤红斑狼疮、皮炎、哮喘、炎性疾病
Regional status
US
临床三期
2010-10-01
EU
-
China
批准上市
1981-01-01
Japan
批准上市
1981-09-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Betamethasone?
Approved indications include: 溃疡性直肠炎, 超敏反应, 类风湿关节炎, 皮肤红斑狼疮, 皮炎, 哮喘, 炎性疾病.
When does the Betamethasone patent expire?
No public expiry year is available for Betamethasone yet; this page updates once verified.
How do I get a quote for Betamethasone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25